WCLC 2023

IASLC WCLC 2023 Conference - Tagrisso, a targeted therapy, combined with chemotherapy, extended the median progression-free survival by nearly 9 months in patients with EGFR-mutated advanced lung cancer, according to the FLAURA2 Phase III trial.
Conferences Pharma

Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)

Anika Sharma

Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...

IASLC WCLC 2023 Conference - Fasenra, a biologic medicine, met the primary endpoint of inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe inflammatory disease.
Conferences Pharma

Fasenra, a new treatment for EGPA, achieved remission in Phase III trial (IASLC WCLC 2023 Conference)

Anika Sharma

The MANDARA Phase III trial has shed new light on the effectiveness of AstraZeneca’s Fasenra (benralizumab). Unveiling favorable high-tier outcomes, ...

Pharmtales - your go-to source for comprehensive coverage of the pharmaceutical industry.

pharmtales
Latest Pharma News & Insights

© 2025 pharmtales.com | All rights reserved.

PRIVACY POLICY terms of service Contact us